SCHEMBL20740702

SCHEMBL20740702

CCCCCCCCNc1nc(Cl)nc(OCCCCCCCC)n1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
DNM2 P50570 9/20 0.43
KCNH3 Q9ULD8 2/20 0.42
NR1I2 O75469 1/20 0.40
AHR P35869 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17564584 0.90 KMT2A (0.49) KMT2AMAPTHTTNPSR1DNM2
SCHEMBL9789568 0.84 KMT2A (0.54) KMT2AMAPTHTTNPSR1NR1I2
SCHEMBL9789554 0.84 KMT2A (0.54) KMT2AMAPTHTTNPSR1NR1I2
SCHEMBL11787843 0.82 KMT2A (0.83) KMT2AMAPTHTTNPSR1DNM2
SCHEMBL11652521 0.82 NR5A1 (0.40) KMT2AMAPTLMNAALDH1A1
SCHEMBL7937257 0.82 KMT2A (0.77) KMT2ADNM2KCNH3NR1I2AHR
SCHEMBL1562316 0.82 KMT2A (0.77) KMT2ADNM2KCNH3NR1I2AHR
SCHEMBL17563553 0.82 KMT2A (0.77) KMT2ADNM2KCNH3NR1I2AHR
SCHEMBL11395631 0.82 NR5A1 (0.40) KMT2AMAPTLMNAALDH1A1
SCHEMBL17563551 0.82 NR5A1 (0.40) KMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299504-B2 Process for preparing a triazine-based precursor, the precursor prepared thereby, a method for producing a micro-particulate complex using the precursor, and the micro-particulate complex produced thereby NATIONAL CHI NAN UNIVERSITY (TW) 2022-04-12 US disclosed
CN-109400543-B Triazine precursor, method for preparing triazine precursor and application of triazine precursor 暨南国际大学 2022-03-01 CN disclosed
US-20200369687-A1 Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby NATIONAL CHI NAN UNIVERSITY (TW) 2020-11-26 US disclosed
US-20190055270-A1 Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby NATIONAL CHI NAN UNIVERSITY (TW) 2019-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055270-A1 Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby SSRP1, RRP15, SUB1 KMT2A 2946/4885MAPT 1446/4885HTT 1166/4885
US-11299504-B2 Process for preparing a triazine-based precursor, the precursor prepared thereby, a method for producing a micro-particulate complex using the precursor, and the micro-particulate complex produced thereby SSRP1, RRP15, SUB1 KMT2A 2946/4885MAPT 1446/4885HTT 1166/4885
US-20200369687-A1 Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby SSRP1, RRP15, SUB1 KMT2A 2946/4885MAPT 1446/4885HTT 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.